Moneycontrol PRO
HomeNewsCovid vaccine

Covid Vaccine

Jump to
  • ‘Incorrect, Misleading’: ICMR Seeks Retraction Of BHU Study On Covaxin Side Effects, Warns Of Legal Action

    ICMR said that it has noticed that the BHU's authors have acknowledged ICMR in similar previous papers without permission. It has asked for an explanation on why ICMR should not seek legal and administrative action against the authors. The BHU said it is aware of the communication made by the ICMR to the individuals concerned and its Institute of Medical Sciences is looking into the matter. The university also added that it is working on improving its research ecosystem

  • German man receives 217 Covid vaccinations in 29 months: What hypervaccination study reveals

    The man's hypervaccination came to light when the public prosecutor in Magdeburg launched an investigation into the matter, suspecting fraudulent activity.

  • Dr Poonawalla did outstanding work in vaccine manufacturing, says Pawar; seeks Bharat Ratna for him

    It is reasonable to expect the government to seriously consider honouring Poonawalla with Bharat Ratna, Pawar said.

  • It’s time scientists admitted their COVID mistakes

    Some public health agencies took years to admit what had quickly become obvious: that the COVID virus was airborne. Others suggested extreme precautions, which had minimal benefits or were hard to implement. Rebuilding trust is not just about clearer, more persuasive communication but also admitting to mistakes 

  • COVID-19 cases cross 10,000 per day but booster vaccination stays sluggish 

    Slow public procurement of COVID-19 vaccines has meant that the only way those eligible can avail the booster is by paying at private hospitals, leading to very low demand for precautionary doses despite rising cases.

  • Odisha seeks 50,000 vaccines from the Centre as COVID-19 cases rise

    The state does not have any vaccine left since February this year, Odisha director of family welfare Bijay Panigrahi wrote, and requested for at least 50,000 doses of CorBEvax vaccine with long expiry as early as possible.

  • Bihar CM Nitish Kumar urges Centre to provide fresh COVID vaccine stocks

    He underscored that the current spike was noticed in those parts of the country which were the worst affected when the coronavirus caused a global pandemic.

  • ICMR's report on deaths due to sudden heart attacks to be out in two months: Mansukh Mandaviya

    The Union minister also said a review of data generated on the subject is being conducted by AIIMS, Delhi, and the report should be out soon.

  • Covid vaccine and rising cases of heart attack: What do the experts say?

    People in their 50s, 40s, 30s, even 20s are being diagnosed with blocked arteries and heart problems. It's important to know the symptoms of heart attack, how to differentiate between different types of chest pain, and what to do if you experience pain that radiates up to your jaw and/or arms.

  • India saved over 3.4 million lives due to unprecedented scale of COVID vaccination: Report

    "A Lancet modelling study estimates that in India around 34,22,00054 deaths were prevented by vaccination in the year 2021, an estimate based on officially reported deaths in India," the report has said.

  • 3 lakh doses of intranasal Covid vaccine sent to hospitals: Bharat Biotech's Krishna Ella

    He was speaking on the sidelines of an event here at which a bilateral agreement was signed between the University of Wisconsin (UW)-Madison Global Health Institute (GHI) and the Ella Foundation for the establishment of the first-ever UW-Madison One Health Centre in Bengaluru.

  • A better anti-coronavirus vaccine needed to prevent transmission and long COVID

    A treatment that's more effective would be a huge advance. It’s time to put real resources into developing vaccines that offer longer-term protection

  • Jairam Ramesh hits back after minister accuses Congress of pushing foreign vaccines' case during Covid

    Tagging a video of Pfizer CEO Albert Bourla's encounter with a journalist in Davos, Chandrasekhar said on Twitter that the pharmaceutical company tried to bully the Indian government into accepting conditions of indemnity.

  • MC Exclusive | Bharat Biotech’s intranasal COVID-19 vaccine likely to be available only in corporate hospitals in major cities

    Due to lack of rise in demand for booster doses, small private hospitals have showed no interest in procuring the vaccine despite the ease of administration it promises, say industry sources

  • Ocugen-Bharat Biotech COVID vaccine meets main goals in US trial

    The vaccine, sold under brand name Covaxin, showed an immune response in individuals who had not received a COVID vaccine previously as well as those vaccinated with mRNA vaccines by Pfizer Inc and Moderna Inc, meeting its main goals, Ocugen said.

  • Bharat Biotech’s Covaxin inching closer to US launch plan?

    Covaxin was found to be well-tolerated in vaccine-naïve individuals and in individuals previously vaccinated with mRNA vaccines in the US with no vaccine-related serious adverse events, Bharat Biotech’s partner in the country has announced

  • Fourth Covid vaccine dose unwarranted right now but increased surveillance needed: experts

    As Covid gets back on the radar with a surge in China and people worry about another wave in India and whether the government should now allow a second booster shot to add to the two-jab protection, some scientists call for a reality check.

  • Bharat Biotech's intranasal Covid vaccine as a booster approved by govt, to be available on CO-WIN

    The needle-free vaccine will be available at private hospitals as of now and can be administered as a precaution dose to adults who have been vaccinated with two doses of either Covishield or Covaxin.

  • Bharat Biotech's nasal vaccine to be available as booster for 18+ as India readies for another pandemic test

    The Hyderabad-based Covaxin maker’s nasal vaccine will be introduced on Co-WIN by next week, sources said, adding that the pricing is yet to be decided

  • COVID-19: Fresh push to booster shots for adults; focus this time on mix-and- match doses

    COVID-19: Even though the explosion of coronavirus cases in China has triggered global concerns, India has maintained that there is no need to panic in view of the extensive vaccine coverage. The government has, however, urged people to stay alert and follow COVID-appropriate behaviour

  • First foreign COVID vaccines head to China from Germany

    No other details were available on the timing and size of the delivery, although the spokesperson said Berlin is pushing for foreigners other than German citizens to be allowed access to the shot if they want it.

  • Only 27-28% beneficiaries have taken precaution dose of COVID-19 vaccine

    The Union health minister on December 21 reviewed the COVID-19 situation in the country and asked people to follow COVID-appropriate behaviour, including wearing masks in crowded places, and getting vaccinated.

  • German panel recommends COVID-19 shot only for at-risk youngsters

    The head of the panel of 18 appointees, known as STIKO, said there was no clear case for broad use, citing a lack of data to rule out any rare side effects and no signs of the infection causing severe illness in otherwise healthy children.

  • Infosys co-founder Narayana Murthy says death of 66 children in Gambia shamed India

    Narayana Murthy said in his speech announcing the winners of the Infosys Science Prize that the IITs have become victims of the syndrome of rote learning due to the tyranny of coaching classes.

  • World’s first Covid vaccine you inhale is approved in China

    China’s National Medical Products Administration approved CanSino’s Ad5-nCoV for emergency use as a booster vaccine, the company said in a statement to the Hong Kong Stock Exchange on Sunday.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347